Summary
Edwards Lifesciences Corporation's (EW) Form 10-Q filing for the period ending June 29, 2019, demonstrates robust top-line growth, with total net sales increasing by 15.2% to $1,086.9 million for the quarter and 13.1% to $2,079.9 million for the six-month period. This growth was primarily fueled by strong performance in the Transcatheter Aortic Valve Replacement (TAVR) segment, driven by increased sales of the Edwards SAPIEN 3 and SAPIEN 3 Ultra Systems, and solid contributions from Surgical Structural Heart and Critical Care products. While revenue grew, net income saw a decrease of 14.3% to $242.3 million for the quarter, impacted by a prior year tax benefit and a current year inventory charge related to strategic portfolio decisions, including the discontinuation of the CENTERA program. Despite the dip in quarterly net income, the company's balance sheet remains solid, with total assets growing to $5,573.5 million. The company also completed the acquisition of CAS Medical Systems, Inc. (CASMED) for approximately $100 million, enhancing its critical care monitoring capabilities. Management expresses confidence in the company's liquidity to fund its ongoing operations and capital expenditures for the next twelve months, supported by strong operating cash flow generation. Investors should monitor the ongoing litigation with Abbott Laboratories as a potential risk factor.
Financial Highlights
51 data points| Revenue | $1.09B |
| Cost of Revenue | $304.00M |
| Gross Profit | $782.90M |
| R&D Expenses | $191.90M |
| SG&A Expenses | $308.50M |
| Operating Income | $267.50M |
| Net Income | $242.30M |
| EPS (Basic) | $0.39 |
| EPS (Diluted) | $0.38 |
| Shares Outstanding (Basic) | 624.40M |
| Shares Outstanding (Diluted) | 636.20M |
Key Highlights
- 1Total net sales increased by 15.2% to $1,086.9 million in Q2 2019 and by 13.1% to $2,079.9 million in the first six months of 2019, driven by TAVR and Surgical Structural Heart product lines.
- 2Transcatheter Aortic Valve Replacement (TAVR) sales saw a significant increase of 16.0% ($93.7 million) for the quarter and 12.4% ($140.3 million) for the six-month period, largely due to strong adoption of the SAPIEN 3 and SAPIEN 3 Ultra Systems.
- 3Net income for the quarter decreased by 14.3% to $242.3 million, impacted by an inventory charge related to strategic portfolio decisions and a prior year tax benefit.
- 4The company completed the acquisition of CAS Medical Systems, Inc. (CASMED) for approximately $100.8 million, expanding its critical care monitoring offerings.
- 5Research and Development (R&D) expenses increased, reflecting continued investment in transcatheter structural heart programs and clinical trials.
- 6Operating cash flow for the six months ended June 30, 2019, increased by $51.2 million to $342.7 million, primarily due to higher tax payments in the prior year and improved operating performance.
- 7Edwards Lifesciences is actively defending itself against multiple patent infringement lawsuits filed by Abbott Laboratories concerning the PASCAL heart valve repair system.